The government said it is considering expanding the scope of the prescription for Paxlovid, an oral treatment for COVID-19, to "underlying patients aged 12 or older." However, considering the fact that there are side effects, it is said that various decision-making processes such as collecting opinions from experts should be carried out.

This revealed the government's position on the presidential transition committee's announcement that it is considering expanding the prescription of the treatment to those with underlying diseases over the age of 12. Lee Sang-won, head of the epidemiological investigation and analysis team at the Central Disease Control Headquarters, explained at a regular briefing on t